Early-onset Alzheimer's Disease
Early-onset Alzheimer's disease (EOAD) is a form of dementia that affects people under 65, leading to memory loss, confusion, and changes in behavior and personality.
Early-Onset Alzheimer's Disease: ALN-APP Treatment
We are evaluating the safety and tolerability of a new treatment called ALN-APP for patients with early-onset Alzheimer's disease. This study aims to understand how well the treatment is tolerated in humans.
Safety phase (I)Neurology
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Brain Research Center Amsterdam B.V.
Neurology
Amstelveen, Netherlands
Sponsor: Alnylam Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.